- SOHM just announced the appointment of Wm. Dewey Rushing as the new VP-Quality
- His appointment follows the recent nomination of Dr. Krishna Bhat as the new Chief Medical Advisor and Dr. David Aguilar as the new COO
- It also follows the recently signed LOI for SOHM to acquire ABBIE stem cell disruptive technology and patents from CGA Intellectual Holdings Inc.
SOHM (OTC: SHMN), a generic drug manufacturing and distributing innovator, is bolstering its executive team as it eyes the global nutraceuticals market, which is expected to post a CAGR of 9.4% between 2023 and 2030, and the global NSAID market which is also expected to be valued at $30 billion by 2030. SOHM’s strategic approach has seen it bring experts on board, some of whom have previously served in advisory capacities within the company and have a good understanding of its ethos, vision, and overall approach to solving client problems.
On September 11, the company announced the appointment of Wm. Dewey Rushing as the new Vice President-Quality. Mr. Rushing previously served as an Advisory Board member at the company since 2022. His years of experience in cell therapy IND readiness, quality systems audits, aseptic processing, and cGMP compliance and regulation make him a valuable asset to the company, mainly as it explores the next steps for growth (https://ibn.fm/YQ86u).
While announcing his appointment, Baron Night, SOHM’s President and CEO, lauded Mr. Rushing’s value to the company, noting how instrumental he has been in providing his expertise on validation and compliance issues.
“SOHM has appointed him [Mr. Rushing] as the Vice President of Quality, recognizing his exceptional qualifications and experience in pharmaceutical quality validation and cGMP compliance,” noted Mr. Night.
Mr. Rushing’s appointment follows the recent appointment of Dr. Krishna Bhat (MD, Ph.D., FACC as the company’s new Chief Medical Advisor and Dr. David Aguilar (Ph.D.) as the new Chief Operating Officer (“COO”) (https://ibn.fm/ZFLRS). These are all in a bid to strengthen the company’s governing team while propping it for success as it expands on the most ambitious phase of the company’s progression.
SOHM also recently signed a letter of intent (“LOI”) to acquire A Binding Based Integrating Enzyme (“ABBIE”) stem cell disruptive technology and patents from CGA Intellectual Holdings Inc. This would allow it to create novel products and solutions in the regenerative medicine and cosmeceutical industries, a useful asset in SOHM’s growing portfolio (https://ibn.fm/4o6Fk). The three appointments will be integral in leveraging this product, bringing it to market, and even utilizing it to create novel products and solutions for customers.
SOHM envisions a future where it evolves into a prominent global corporation with corresponding market reach, while maintaining its fundamental core values. So far, it is on track to extend its export portfolio to 11 countries, a milestone that reflects its growing expertise. These recent appointments build on the success and the momentum gained so far, and management is increasingly confident about anticipated developments and opportunities.
For more information, visit the company’s website at www.SOHM.com.
NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN
